Your browser doesn't support javascript.
loading
Cefaclor treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis.
Oberlin, J A; Hyslop, D L.
Affiliation
  • Oberlin JA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.
Pediatr Infect Dis J ; 9(1): 41-4, 1990 Jan.
Article in En | MEDLINE | ID: mdl-2105479
A retrospective analysis of data from 18 clinical studies was performed to examine the effectiveness and safety of cefaclor in the treatment of upper and lower respiratory tract infections caused by Moraxella catarrhalis (previously called Branhamella catarrhalis). Eighty-six percent of 56 evaluable patients had improvement in their symptoms of infections following therapy with cefaclor. There were no serious or life-threatening adverse drug experiences reported by any patient. Cefaclor appears to be an appropriate antibiotic for the safe and effective treatment of respiratory tract infections caused by M. catarrhalis.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Bacterial Infections / Cefaclor / Cephalexin Type of study: Observational_studies Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 1990 Document type: Article Country of publication: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Bacterial Infections / Cefaclor / Cephalexin Type of study: Observational_studies Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Language: En Journal: Pediatr Infect Dis J Journal subject: DOENCAS TRANSMISSIVEIS / PEDIATRIA Year: 1990 Document type: Article Country of publication: United States